Latest Triangle Pharmaceuticals News
Jan 9, 2020
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2003--GileadSciences, Inc. (Nasdaq:GILD) announced today that it has completedits acquisition of Triangle Pharmaceuticals, Inc. (Nasdaq:VIRS) bymerging Triangle with a wholly owned subsidiary of Gilead. The mergerfollows a cash tender offer for all outstanding shares of Trianglecommon stock at $6.00 per share, which was completed at midnight, NewYork City time, on January 15, 2003. As a result of the merger, eachoutstanding share of Triangle not owned by Gilead, its subsidiaries orTriangle has been automatically converted into the right to receive$6.00 in cash, without interest, subject to appraisal rights. Trianglestockholders who did not tender their shares will receive a Notice ofMerger and a Letter of Transmittal that will instruct them as to howto receive the merger consideration. About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers,develops and commercializes therapeutics to advance the care ofpatients suffering from life-threatening diseases worldwide. Thecompany has six marketed products and focuses its research andclinical programs on anti-infectives. Headquartered in Foster City,CA, Gilead has operations in the United States, Europe and Australia. For more information on Gilead, please call the Gilead PublicAffairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visitwww.gilead.com. --30--am/sf*
Triangle Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Triangle Pharmaceuticals's headquarters?
Triangle Pharmaceuticals's headquarters is located at 4 University Place, Durham.
What is Triangle Pharmaceuticals's latest funding round?
Triangle Pharmaceuticals's latest funding round is Acquired.
How much did Triangle Pharmaceuticals raise?
Triangle Pharmaceuticals raised a total of $155.66M.
Who are the investors of Triangle Pharmaceuticals?
Investors of Triangle Pharmaceuticals include Gilead Sciences, Warburg Pincus, Point72 Asset Management, Merlin Biomed Group, QFinance and 11 more.